Parse Biosciences launches single-cell immune profiling products

US-based Parse Biosciences, a leading provider of accessible and scalable single-cell sequencing solutions, has announced the availability of Evercode BCR and the expansion of its existing product line, Evercode TCR. The new BCR solution and updates to the existing TCR product line expand Parse's single-cell portfolio and enable researchers to study the immune repertoire at unprecedented resolution and scale.

Evercode BCR allows researchers to capture B-cell receptor (BCR) sequences and gene expression in the same cells. While existing tools struggle to capture the immense diversity of the BCR repertoire, Evercode BCR offers a breakthrough by measuring paired BCR sequences (heavy and light chains) in up to one million cells in a single experiment. This evolutionary approach allows BCR clonotypes to be assigned to various B cell subtypes and activation states, providing unprecedented resolution and opening up new possibilities for antibody discovery.

Parse has also expanded its Evercode TCR product line to enable detection of mouse and human TCRs, significantly improving performance. These updates provide increased sensitivity for the detection of gene expression and TCRs and build on the recent release of version 3 chemistry of its flagship product, Evercode Whole Transcriptome.

Because both Evercode BCR and TCR are compatible with fixation, researchers can fix and store samples as soon as they arrive, and then batch them together in a single experiment. This allows experiments to be performed on time cycles and at higher throughput, while minimising potential batch effects between samples.